MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_01C96ACC.685AE5F0" 此文件是「單一檔案網頁」,亦稱為「網頁封存檔案」。若看到此訊息,表示您的瀏覽器或編輯器不支援「網頁封存檔案」。請下載支援「網頁封存」的瀏覽器,例如 Microsoft Internet Explorer。 ------=_NextPart_01C96ACC.685AE5F0 Content-Location: file:///C:/A398DA58/080518.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
IN THE =
AU INTELLECTUAL PROPER=
TY
OFFICE
A/Supervising Examiner  = ; &n= bsp;  = ; &n= bsp; Patent Examination B / B3 - Pharmaceuti= cals In re PATENT APPLICATION of: Applicant(s) &nbs= p; : Z= span>hen-man Lin = &nb= sp; = &nb= sp; ) Application No. &=
nbsp; : 2003248601 &nbs=
p; &=
nbsp; &nbs=
p; &=
nbsp; &nbs=
p; ) Respond for First PCT Filed Date := 12. 06, 2003 &nb= sp; = &nb= sp; = = span>) examination For &= nbsp; &nbs= p; : S= urface Treatment of SARS-Infected Lungs ) Patent Examination B &nbs= p; &= nbsp; &nbs= p; Fax: 61-2-6283-7999 B3 – Pharmaceuticals Dear Madam/Sir I = had received the first examination report on 24 March 2007. It was regarding the post time, = so the sign-date of report it shown 13 March 2007. I have attached a payment form t= o pay the fee of AUD $100 for filing a response to an examination report more than 1 month. Unde=
r the comment<=
span
lang=3DEN-US style=3D'color:maroon'> 1.of the Examination Report is below:
《 1. You have n= ot supplied me with a Notice of Entitlement which makes it clear that you are entitled to have a patent granted to you. In the Notice of Entitlement you = will need to state either that you are the actual inventor or how you gained t= he right to apply from the actual inventor.》 Respond IBe= cause this is a case of PCT application in AU office, by the documents of PCT r= ule, which could show that the actual inventor and the applicant is the same p= erson, please do acknowledge this. Under the comment 2.of the Examination Report is below: = span>《 From a reading of your applicatio= n, it appears that the invention resides in the use of compositions comprising ozone and a per fluorocarbon solvent in the surface treatment of SARS-inf= ections. On that basis I have carried out a search of the available prior an, and = am of the opinion that the invention that you have claimed is not inventive = in view of G. V. SUNNEN, SARS and Ozone Therapy: Theoret= ical Considerations, May 2003. Retrieved from the internet: <URL: http://www.triroc.= com/sunnen/topics/sars.html>. This citation disclos= es the use of ozone in the treatment of SARS infections. The only difference bet= ween your claimed invention and the citation is the use of a perfluorocarbon solvent. Such solvents are known as drug delivery systems in lung disease (see for example "Pulmonary Drug Delivery", N. K. Ghilzai, a review accessed http://www.drugdel.com/Pu= lm_review.pdf ), and your application provides no apparent inventiveness in their application to the present treatment. In the absence of some unexpected advantage, an inventive step cannot be acknowledged.》 Respond II. Firstly, the document of network is not recognized by any official= !And it is always difficult to distinguish the true and false, so it cannot to gi= ve the priority qualifications in patent field; S <=
span
lang=3DEN-US style=3D'color:blue;mso-bidi-font-weight:bold'>http:=
//www.ycec.com/Surface-Treatment-of-SARS-hk200503.htm 『 Since F=
ebruary
2003 years, SARS infection has wreaks havoc in China, Hong Kong and many other countries in the world. Its ef=
fects
had send repercussion throughout the entire international society. The death rate has been high and=
the
Chinese and western medical social were quite helpless about this. So China, Taiwan, Hong Kong, Singapore and
Canada etc. were listed on travel warning district by World Health
Organization and pecuniary loss surmount thousand a hundred million, Mank=
ind
is faced with death threat. Knowing how to treat=
the
SARS virus infection had became the top most urgent matter in the <=
span
style=3D'mso-spacerun:yes'> So=
that
is to say, the invention specification delivered mail to WHO
meeting on 20th May 2003.
Under the convention of patent-application, the right of priority =
of
our invention application could be extend to t=
he
date. Besides, this invention was to grant the patent from the Hong Kong
Government on 23th July. 2004, the patent num=
ber is
HK1060833, so the promulgate date of this patent on 15th May, 2003 was to get the indirect admit by a
official. This important date will write down in history for proclaim man=
kind
society to defeat the SARS and bird-flu already! Please see website of
inventor: =
http:=
//www.ycec.com/Surface-Treatment-of-SARS-hk200503.htm
About the "Pulmonary Drug Delivery" of http://www.drugdel.com/Pu=
lm_review.pdf
that was uncompl=
icated and the Drug Delivery not a Drug invent, besides, this do=
cument
of network is always not recognize by any official too! In conclusion, under the comment 3.of the Examination Report those
raise to amend specification.
After I t=
hink it over,
except for the claims1-5 which will amend again=
, the specification
include abstract=
and total 1-6 figure which no have any change and it same t=
he
list D. of application document with a letter sent to office on 16 June
2005. &nbs=
p;
Please see the above statement for amendment of PCT, except for
the claims that specification include abstract and all=
Figure
which no have any change. P=
lease
see the Marked-up and substitute Claims of attach 1-2., the underlined sh=
ow
add and square b=
racket
to show delete, the total five claims were to add for total six claims, <=
/span>kindly amend so as not to bring any new matter. <=
span
style=3D'mso-spacerun:yes'> For the foregoi=
ng
reasons, it is respectfully submitted that the application is now in
condition for allowance.
Reconsideration of the application is therefore respectfully
requested. Yours
faithfully, &nbs=
p;
Applicant
and inventor: Lin Zhen Man &nbs=
p; &=
nbsp; &nbs=
p;
18 May. 2008 &nb=
sp;
pm 09:30 Fax: 61-2-6283-7999 |
Attach 1 A marked-up copy of the amend claims on 15 June 2005 =
Claims
in AU patent office
1.= In the lungs infected disease field, a liquid medicine of formulation for the Surface Tre= atment of SARS-Infected comprising is Per Fluoro Chemicals (PFC) mixing ozone. 2.= A formulation as claime= d in claim 1 wherein the same is in liquid form and includes all liquids of fluorine element. 3.= A formulation as claime= d in anyone of 1 or 2 comprising any substitute liquid to mixing ozone or the single oxygen is decomposed by other element. 4.= A formulation as claime= d in anyone of claims 1 to 3 comprising medicaments selected from anti bacteri= al agents, antibiotics and lung infection/inflammation curing agents. 5.= The Liquid medicine/formulation for the Surface Treatment of SARS-Infected Lungs substantially as herein described and illustrated with reference to the accompanying examples and figures. 6.=
A formulation as cla=
imed
by anyone from claim 1 to 5 comprises any other lung diseases and SARS
inflammation. |
Attach 2.<=
/span> Substitute copy of the claims on 18 May. 2008 =
Claims
in AU
1.= In the lungs infected d= isease field, a liquid medicine of f= ormulation for the Surface Treatment of SARS-Infected comprising is Per Fluoro Chemicals (PFC) mixing ozone. 2.= A formulation as claime= d in claim 1 wherein the same is in liquid form and includes all liquids of fluorine element. 3.= A formulation as claime= d in anyone of 1 or 2 comprising any substitute liquid to mixing ozone or the single oxygen is decomposed by other element. 4.= A formulation as claime= d in anyone of claims 1 to 3 comprising medicaments selected from anti bacteri= al agents, antibiotics and lung infection/inflammation curing agents. 5.= The Liquid medicine/formulation for the Surface Treatment of SARS-Infected Lungs substantially as herein described and illustrated with reference to the a= ccompanying examples and figures. 6.= A formulation as claime= d by anyone from claim 1 to 5 comprises any other lung diseases and SARS inflammation. |
IN THE =
AU INTELLECTUAL PROPER=
TY
OFFICE
A/Supervising Examiner  = ; &n= bsp;  = ; &n= bsp; Patent Examination B / B3 - Pharmaceuti= cals In re PATENT APPLICATION of: Applicant(s) &nbs= p; : Z= span>hen-man Lin = &nb= sp; = &nb= sp; ) Application No. &= nbsp; : 2003248601 &nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; ) Respond for PCT Filed Date := 12. 06, 2003 &nb= sp; = &nb= sp; = = span>) Fees notify For &= nbsp; &nbs= p; : S= urface Treatment of SARS-Infected Lungs ) Electronic Records Administration &nbs= p; &= nbsp; &nbs= p; Fax: 61-2-6283-7999 Dear Madam/Sir I have received your letter which= is dated 16 April 2008. I have found t=
he
page 6 of “PCT Applicant’s Guide – Volume II ̵=
1;
National Chapter – AU” which states that the annual fee=
span> of Continuation/renewal is from the 5th=
to
19th anniversary, this fee was paid =
after
a patent granted to Applicant
and all pct contract country for the most part the same. I think it was=
a mistake made by your el=
ectronic
records, please notify me again after you have made a thorough investigation of
Yours
faithfully, &nbs=
p;
Applicant and inventor: Lin Zhen Man &nbs= p; &nbs= p; &= nbsp; &nbs= p; 18 May. 2008 &nb= sp; pm 09:30 Fax: 61-2-6283-7999 |
HKBN EsendFa=
x
Service SUCCESSFUL Transmission Confirmat=
ion |
.
&nb=
sp;